Ann: Kazia presentation to Bell Potter Healthcare Conference, page-4

First 4 Last

Share
Profile

Follow
onesurfed

2,071 Posts.

443

26/11/20

09:46

Post #: 49155096
Share

Originally posted by needle: ↑

They are still sticking with the Dana Farber Breast Brain Cancer, this quarter.

But a note that the slides were as of Oct 30.....60/40 for me, we will get this update, in the next 10 days or so.

The recent announcements which so strongly moved the share price.....were all in part previously discussed here, prior to the company announcements. eg Paxalisib GBM results were the same as April....see below:

Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.

-----

This forthcoming brain metastases - possibility data, is on a COMPLETELY different scale to GBM treatment or those strong SP movement announcements from the FDA.

Dana Farber moving forward with this trial is all we need. A positive report feeds into the ALLIANCE trial being conducted by Priscilla Brastanious in ALL CANCERS, whereby primary cancers move to the brain. The drug Paxalisib has potential for use in hundreds of thousands of brain mets sufferers .....so what we here from Dana Farber has huge implications for the company.

Expand

Several months ago I called on Bell Potter to provide a valuation update. They usually do every quarter, and I'm thinking they will soon.

KZA Price at posting: $1.34 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

RCE

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

There are more pages in this discussion • 24 more messages in this thread...

First 4 Last

Add KZA (ASX) to my watchlist

Ann: Kazia presentation to Bell Potter Healthcare Conference, page-4

Top Stories

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Ava Risk Group expands US presence with A$0.7M Substation Deal

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Featured News